🇺🇸 FDA

Company profile · Sponsor

Matinas

Matinas BioPharma Holdings

MTNB · NYSE biotech BEDMINSTER, NJ, USA
Pipeline
9
Drugs
0
Patents
8

Quick answer

Matinas (MTNB) is a biotech company. headquartered in BEDMINSTER, NJ, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker MTNB
Exchange NYSE
Company type biotech
Headquarters BEDMINSTER, NJ, USA
SEC CIK 0001582554

Pipeline (9)

Search pipeline →

  1. MAT2203

    Matinas

    Cryptococcal Meningitis

    phase 3 small molecule active

    2 trials

  2. Placebo

    Matinas

    Severe Hypertriglyceridemia

    phase 3 small molecule terminated

    1 trial

  3. Amphotericin B

    Matinas

    Candidiasis, Chronic Mucocutaneous

    phase 2 small molecule completed

    1 trial

  4. Drug Omega 3

    Matinas

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  5. Encochleated Amphotericin B

    Matinas

    Cryptococcal Infections

    phase 2 small molecule terminated

    1 trial

  6. Omega 3 pentaenoic acid

    Matinas

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  7. Oral Encochleated Amphotericin B (CAMB)

    Matinas

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  8. Oral Encochleated Amphotericin B (CAMB)

    Matinas

    Vulvovaginal Candidiases

    phase 2 small molecule terminated

    1 trial

  9. Oral Encochleated Amphotericin B (CAMB)

    Matinas

    Vulvovaginitis

    phase 2 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12409227

    Cochleates made with soy phosphatidylserine

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11964019

    Cochleates made with soy phosphatidylserine

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11389407

    Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11123295

    Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10716860

    Cochleates made with soy phosphatidylserine

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10058521

    Omega-3 pentaenoic acid compositions and methods of use

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9775907

    Cochleates made with soy phosphatidylserine

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8906964

    Methods of administering compositions comprising docosapentaenoic acid

    Expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Matinas?

Matinas (MTNB) is a biotech company. headquartered in BEDMINSTER, NJ, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Matinas sponsor?

We track 9 ClinicalTrials.gov-linked programs for Matinas, including MAT2203 and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Matinas company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.